Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Kidney injuries related to ipilimumab.

Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A, Rouvier P.

Invest New Drugs. 2014 Aug;32(4):769-73. doi: 10.1007/s10637-014-0092-7. Epub 2014 Apr 1.

PMID:
24687600
2.

Management of immune-related adverse events and kinetics of response with ipilimumab.

Weber JS, Kähler KC, Hauschild A.

J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. Review.

PMID:
22614989
3.

Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.

Weber JS.

Am Soc Clin Oncol Educ Book. 2012:174-7. doi: 10.14694/EdBook_AM.2012.32.174.

4.

Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.

Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM.

Ocul Immunol Inflamm. 2016;24(2):140-6. doi: 10.3109/09273948.2014.1001858. Epub 2015 Mar 11. Review.

PMID:
25760920
5.

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

Di Giacomo AM, Biagioli M, Maio M.

Semin Oncol. 2010 Oct;37(5):499-507. doi: 10.1053/j.seminoncol.2010.09.007. Review.

PMID:
21074065
6.

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.

Kähler KC, Hauschild A.

J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86. doi: 10.1111/j.1610-0387.2010.07568.x. Epub 2010 Nov 17. Review. English, German.

PMID:
21083648
7.

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.

Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M.

Cancer Immunol Res. 2015 Oct;3(10):1185-92. doi: 10.1158/2326-6066.CIR-15-0102. Epub 2015 Jun 22.

8.

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

Makarious D, Horwood K, Coward JIG.

Eur J Cancer. 2017 Sep;82:128-136. doi: 10.1016/j.ejca.2017.05.041. Epub 2017 Jun 27. Review.

PMID:
28666240
9.

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T.

BMC Med. 2015 Sep 4;13:211. doi: 10.1186/s12916-015-0455-8. Review.

10.

Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Quirk SK, Shure AK, Agrawal DK.

Transl Res. 2015 Nov;166(5):412-24. doi: 10.1016/j.trsl.2015.06.005. Epub 2015 Jun 11. Review.

11.

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd.

Ann Rheum Dis. 2017 Jan;76(1):43-50. doi: 10.1136/annrheumdis-2016-209595. Epub 2016 Jun 15.

12.

Management of toxicities of immune checkpoint inhibitors.

Spain L, Diem S, Larkin J.

Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6. Review.

PMID:
26874776
13.

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D.

Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003. Review. Erratum in: Semin Oncol. 2012 Oct;39(5):625.

PMID:
21074064
14.

Ipilimumab-induced toxicities and the gastroenterologist.

Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N.

J Gastroenterol Hepatol. 2015 Apr;30(4):657-66. doi: 10.1111/jgh.12888. Review.

PMID:
25641691
15.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
16.

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.

PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.

17.

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Byun DJ, Wolchok JD, Rosenberg LM, Girotra M.

Nat Rev Endocrinol. 2017 Apr;13(4):195-207. doi: 10.1038/nrendo.2016.205. Epub 2017 Jan 20. Review.

19.

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.

Abdel-Wahab N, Shah M, Suarez-Almazor ME.

PLoS One. 2016 Jul 29;11(7):e0160221. doi: 10.1371/journal.pone.0160221. eCollection 2016. Review.

20.

Endocrine side effects induced by immune checkpoint inhibitors.

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F.

J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75. doi: 10.1210/jc.2012-4075. Epub 2013 Mar 7. Review.

PMID:
23471977

Supplemental Content

Support Center